Common Questions About the Viagra Connect Questionnaire
Of these, 430 pharmacies agreed to participate in the study. For enrollment of Participants in the survey, 33,690 patient survey invitation leaflets were sent to 130 registered pharmacies between 18 September 2020 and 08 October 2020 in wave one (ie, 1st batch of mailing) and 58,258 invitation leaflets were sent to 300 registered pharmacies between 17 May 2020 and 15 June 2021 in wave two (ie, 2nd batch of mailing).
- Viagra Connect is an over-the-counter treatment for erectile dysfunction.
- It contains sildenafil, which improves blood flow to the penis.
- Available in pharmacies without a prescription.
- Patients should consult a pharmacist before use.
- Suitable for men aged 18 and over.
- Must be taken at least 30 minutes before activity.
Wave two mailing was added because the number of participants did not reach the 300 targets in wave one. A total of 412 patients were screened for eligibility, of which 73.5% (n = 303) of them met the inclusion criteria. About 98.0% (n = 297/303) of the study participants completed the survey while 2.0% of them (n = 6) initiated the survey but did not complete it.
What do Sildenafil 50mg Tablets contain?
Of the 19.2% (n = 57) participants who reported having seen their doctors, majority of them (16.8%; n = 50 [12.8–21.6]) viagra jelly sachets uk were told by their doctors that they could continue with VC by buying it at the pharmacy without a prescription, while rest of them (n = 7) were not advised to do so. Among the remaining 35% (n = 104) of the participants, 28.3% (n = 84) of them reported not having seen their doctor and had no plans to discuss VC with their doctor. Patients’ experience with visiting or planning to visit their doctor in the near future are shown (Table 4). Regarding the other additional advice, the participants received from the pharmacists, 85.5% (; n = 254) reported being advised on how to take VC correctly, 82.2% (n = 244) reported that they were advised of possible side effects, for which they might have to discontinue taking VC and consult their doctor. 80.1% (n = 238) reported that their pharmacist informed them that ED can be caused by underlying conditions such as high BP, diabetes, high cholesterol, and heart disease, while 68.7% (n = 204) reported that they had received lifestyle advice from the pharmacist (Table 5).
Warnings and Precautions
Regarding the sources of the knowledge about VC and ED, 31.3% (n = 93) of the participants reported that their pharmacist was the main source of knowledge, while for 26.6% (n = 79) of them it was the product information leaflets in the VC box. Finally, regarding the patients’ comfort in being questioned by the pharmacist, 91.2% of the respondents replied that they agreed or strongly agreed with the statement that they were comfortable to answer questions from the pharmacist. Subgroup analyses for participants responses to the questions regarding pharmacists’ assessment of their suitability for VC, and advice on appropriate use of VC and on their need to see doctors were performed by the stratification of few variables. There was no overlap in the 95% CIs between the subgroups defined by most of the variables, except for the subgroups defined by the two variables, described below. When stratifying the participants by whether the pharmacists asked them if they had ED (82.2% “Yes” vs 9.8% “No”), between-group differences for the participants’ responses to the above-mentioned 4 questions did not overlap between the 95% CIs. The average time to complete this web-based survey was 4.2 minutes, with 72.1% (n = 214) of the participants completed the survey in less than 5 minutes.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 150mg | 10 Pills | 36.73€ 34.98€ | |
| Viagra Super Active | 100mg | 90 + 10 Pills | 165.61€ 157.72€ | |
| Viagra Professional | 100mg | 120 + 4 Pills | 262.83€ 250.31€ | |
| Viagra Generic | 200mg | 30 + 2 Pills | 83.07€ 79.11€ | |
| Viagra Oral Jelly | 100mg | 220 + 18 Sachets | 562.28€ 535.50€ | |
| Viagra Oral Jelly | 100mg | 30 + 5 Sachets | 115.76€ 110.25€ | |
| Viagra Generic | 150mg | 60 + 4 Pills | 111.25€ 105.95€ | |
| Viagra Generic | 50mg | 90 + 6 Pills | 107.37€ 102.26€ | |
| Viagra Oral Jelly | 100mg | 110 + 9 Sachets | 284.63€ 271.08€ | |
| Viagra Generic | 100mg | 180 + 8 Pills | 199.37€ 189.88€ | |
| Viagra Original | 100mg | 4 Pills | 40.94€ 38.99€ | |
| Viagra Super Active | 100mg | 180 + 20 Pills | 280.97€ 267.59€ | |
| Viagra Generic | 25mg | 10 Pills | 25.19€ 23.99€ | |
| Viagra Professional | 100mg | 90 + 2 Pills | 207.09€ 197.23€ |
Patient demographics showed that 45.5% (n = 135) and 41.4% (n = 123) of the participants were in the age group of 41–60 years and 18–40 years, respectively. Symptoms of ED was reported by 86.2% (n = 256) of the participants, 13.8% (n = 41) reported that they were prescribed sildenafil or other ED medication by their doctor and 28.3% (n = 84) reported first purchase of VC from their pharmacist within the last month. Most of the participants reported that the pharmacy they purchased VC for the first time was in an urban area (75.4%; n = 224), was an independent pharmacy (56.2%; n = 167), and the pharmacist was male (61.3%; n = 182). Further details on patient demographics, pharmacy and patient characteristics are shown (Table 1).
VIAGRA Connect 50mg - 8 Tablets
Of these, 430 pharmacies agreed to participate in the study. For enrollment of Participants in the survey, 33,690 patient survey invitation leaflets were sent to 130 registered pharmacies between 18 September 2020 and 08 October 2020 in wave one (ie, 1st batch of mailing) and 58,258 invitation leaflets were sent to 300 registered pharmacies between 17 May 2020 and 15 June 2021 in wave two (ie, 2nd batch of mailing). Wave two mailing was added because the number of participants did not reach the 300 targets in wave one. A total of 412 patients were screened for eligibility, of which 73.5% (n = 303) of them met the inclusion criteria. About 98.0% (n = 297/303) of the study participants completed the survey while 2.0% of them (n = 6) initiated the survey but did not complete it.
Being Serious about Side Effects
The average time to complete this web-based survey was 4.2 minutes, with 72.1% (n = 214) of the participants completed the survey in less than 5 minutes. Patient demographics showed that 45.5% (n = 135) and 41.4% (n = 123) of the participants were in the age group of 41–60 years and 18–40 years, respectively. Symptoms of ED was reported by 86.2% (n = 256) of the participants, 13.8% (n = 41) reported that they were prescribed sildenafil or other ED medication by their doctor and 28.3% (n = 84) reported first purchase of VC from their pharmacist within the last month. Most of the participants reported that the pharmacy they purchased VC for the first time was in an urban area (75.4%; n = 224), was an independent pharmacy (56.2%; n = 167), and the pharmacist was male (61.3%; n = 182). Further details on patient demographics, pharmacy and patient characteristics are shown (Table 1). Participants reported that their pharmacist asked questions about their blood pressure (BP) and heart conditions (91.9%; n = 273), any other illnesses (87.9%; n = 261), or concomitant medications usage (86.5%; n = 257). About 82.2% (n = 244) of the participants reported being asked if they had ED, and 71.7% (n = 213) reported of being asked whether their doctor had advised them about their physical/sexual fitness. Overall, 61.3% (n = 182) of the participants reported being assessed for suitability for VC on all 5 items. The participants’ experience of whether they were assessed for suitability for VC use by their pharmacist the first time they asked for VC is shown (Table 2).
Conflicts of interest
About 35.4% (n=105) of the participants reported being advised to consult their doctor within 6 months of their first supply of VC. Likewise, 11.1% (n = 33) of them reported that they were advised to see their doctor within one month of the first supply, 2.4% (n = 7) of them were advised to see their doctor immediately, and another 2.4% (n = 7) of them were advised to see their doctor within a year of the first supply. About 16.5% (n = 49) of them reported that they were not advised by their pharmacist to see their doctor and 32.3% (n = 96) of them could not recall if they were advised. Patient’s experience of whether they were advised by the pharmacist to consult their doctor during their first request for VC is shown (Table 3). In addition, of the 297 participants, 39.1% (n = 116) reported receiving the tear-off slip with a reminder of when to see their doctor, 23.2% (n = 69) could not remember, and 37.7% (n = 112) stated that they did not receive any tear-off slip. Approximately two-thirds of participants (65.0%; n = 193) reported that they either had seen (19.2%; n = 57) or planned to see (45.8%; n = 136) their doctor. Of the 19.2% (n = 57) participants who reported having seen their doctors, majority of them (16.8%; n = 50 [12.8–21.6]) viagra jelly sachets uk were told by their doctors that they could continue with VC by buying it at the pharmacy without a prescription, while rest of them (n = 7) were not advised to do so. Among the remaining 35% (n = 104) of the participants, 28.3% (n = 84) of them reported not having seen their doctor and had no plans to discuss VC with their doctor. Patients’ experience with visiting or planning to visit their doctor in the near future are shown (Table 4). Regarding the other additional advice, the participants received from the pharmacists, 85.5% (; n = 254) reported being advised on how to take VC correctly, 82.2% (n = 244) reported that they were advised of possible side effects, for which they might have to discontinue taking VC and consult their doctor.
| Step Number | Action | Required Information | Duration | Notes |
|---|---|---|---|---|
| 1 | Visit the Website | None | 2 minutes | Access via desktop or mobile browser |
| 2 | Fill Personal Details | Name, Date of Birth, Address | 3 minutes | Ensure accurate data entry |
| 3 | Medical Questionnaire | Medical history questions | 4 minutes | Privacy is maintained |
| 4 | Confirm Identity | Photo ID upload (if needed) | 5 minutes | May vary based on verification needs |
80.1% (n = 238) reported that their pharmacist informed them that ED can be caused by underlying conditions such as high BP, diabetes, high cholesterol, and heart disease, while 68.7% (n = 204) reported that they had received lifestyle advice from the pharmacist (Table 5).
Sildenafil 50mg - 4 Tablets
Participants reported that their pharmacist asked questions about their blood pressure (BP) and heart conditions (91.9%; n = 273), any other illnesses (87.9%; n = 261), or concomitant medications usage (86.5%; n = 257). About 82.2% (n = 244) of the participants reported being asked if they had ED, and 71.7% (n = 213) reported of being asked whether their doctor had advised them about their physical/sexual fitness. Overall, 61.3% (n = 182) of the participants reported being assessed for suitability for VC on all 5 items. The participants’ experience of whether they were assessed for suitability for VC use by their pharmacist the first time they asked for VC is shown (Table 2). About 35.4% (n=105) of the participants reported being advised to consult their doctor within 6 months of their first supply of VC.
Supplementary Information
Likewise, 11.1% (n = 33) of them reported that they were advised to see their doctor within one month of the first supply, 2.4% (n = 7) of them were advised to see their doctor immediately, and another 2.4% (n = 7) of them were advised to see their doctor within a year of the first supply. About 16.5% (n = 49) of them reported that they were not advised by their pharmacist to see their doctor and 32.3% (n = 96) of them could not recall if they were advised. Patient’s experience of whether they were advised by the pharmacist to consult their doctor during their first request for VC is shown (Table 3). In addition, of the 297 participants, 39.1% (n = 116) reported receiving the tear-off slip with a reminder of when to see their doctor, 23.2% (n = 69) could not remember, and 37.7% (n = 112) stated that they did not receive any tear-off slip. Approximately two-thirds of participants (65.0%; n = 193) reported that they either had seen (19.2%; n = 57) or planned to see (45.8%; n = 136) their doctor. Regarding the sources of the knowledge about VC and ED, 31.3% (n = 93) of the participants reported that their pharmacist was the main source of knowledge, while for 26.6% (n = 79) of them it was the product information leaflets in the VC box.
| Question | Answer | Notes |
|---|---|---|
| Is Viagra Connect available over the counter? | Yes, in select pharmacies and online | Age restriction applies |
| How quickly does it work? | Typically within 30-60 minutes | Varies by individual |
| Are there any side effects? | Yes, includes headache, flushing, nasal congestion | Consult a healthcare provider before use |
| Can I take it with other medications? | Not advised without doctor approval | Possible drug interactions |
Finally, regarding the patients’ comfort in being questioned by the pharmacist, 91.2% of the respondents replied that they agreed or strongly agreed with the statement that they were comfortable to answer questions from the pharmacist.
- Important to check for allergies to sildenafil before use.
- Side effects like dizziness should be taken seriously.
- Consult a doctor if you experience vision changes.
- Viagra Connect does not protect against STDs.
- It’s recommended to avoid caffeine before taking.
- Medication should be used responsibly and as directed.
Subgroup analyses for participants responses to the questions regarding pharmacists’ assessment of their suitability for VC, and advice on appropriate use of VC and on their need to see doctors were performed by the stratification of few variables. There was no overlap in the 95% CIs between the subgroups defined by most of the variables, except for the subgroups defined by the two variables, described below. When stratifying the participants by whether the pharmacists asked them if they had ED (82.2% “Yes” vs 9.8% “No”), between-group differences for the participants’ responses to the above-mentioned 4 questions did not overlap between the 95% CIs.
So, What is the Difference Between Viagra and Viagra Connect?
Also, most respondents (90.1%) reported that they were provided with useful/very useful training materials. They also opined it was an affirmative experience to provide patient counselling about VC. In the current study, we evaluated the effectiveness of the aRMMs program in a survey of ED patients about their interactions with pharmacists when they first purchased VC in pharmacies. The pharmacist survey has been published allowing us to compare the findings between the patient survey and pharmacist survey.14–16 Regarding pharmacists’ assessment of patients’ suitability for VC at the time the patients purchased VC in pharmacies, most patients in the patient survey reported they had been asked about their BP and heart conditions (91.9%), any other illnesses (87.9%) or concomitant medications use (86.5%). In comparison, with the pharmacist survey, the pharmacists’ level of knowledge on the need to ask patients about cardiovascular disease, other illnesses and medication was generally over 80%. In general, if the participants reported having ED, the pharmacists were more likely to assess their suitability for VC and provide advice on appropriate use of VC and on their need to see doctors (Table 6).
| Platform | Type | Availability | Contact Support | Notes |
|---|---|---|---|---|
| Official Pharmacy Website | E-commerce website | 24/7 | Online chat, email | Verified sources |
| Mobile App | App-based ordering | Business hours | In-app support | Convenience for repeat customers |
| Telehealth Consultation | Doctor-assisted purchase | Limited regions | Phone or video chat | Requires medical consultation |
| Third-party Pharmacy Websites | Online retailers | Varies | Support varies | Verify authenticity before purchase |
When stratifying the participants by whether they had been prescribed sildenafil or other ED medication by their doctor (13.8% “Yes”, 78.8% “No”, 7.4% “Do not know/prefer not to answer”), their responses to the question “Since purchasing the FIRST supply of VC from your pharmacist, which of the following are true?” 41.5% of the respondents who reported, vs 12.8% who did not report, having previously been prescribed sildenafil or other ED medication selected the answer “I have seen my doctor and the doctor advised I can continue with sildenafil by buying it at the pharmacy without a prescription”. One of the key strengths of the present study is that it has the benefits of implications from two previously conducted pilot surveys.8,14 The first used a consumer panel and identified significant selection and response biases such that there was a high likelihood that the results would not be representative of the patient population seeking to purchase VC. A second pilot was performed whereby patients were recruited via the pharmacists when the patient was supplied with VC. The survey questions in this second pilot were streamlined to focus only on key questions concerning the advice the pharmacist had provided to the patient, and specifically as to whether the patient was assessed to be suitable for VC and whether he was advised to consult his doctor. Overall, the findings from these pilot surveys aided in restructuring of the methodology including 1) change in recruitment methods, ie through pharmacists, which ensured that only patients who had definitely been supplied with VC were invited, 2) the streamlining of survey questions to focus more specifically on the patients’ experiences while interacting with the pharmacist to purchase VC and minimize the burden to patients, and 3) the patients recruited were supplied from various types of pharmacies in wide geographical locations. The effectiveness of the UK VC aRMMs program has been substantiated by a previous study, a post-authorization safety study (PASS) and regulatory commitment to UK MHRA, which was a cross-sectional survey of pharmacists in the UK who had dispensed VC as a “behind the counter” product to ED patients who purchased it in their pharmacies. It evaluated the pharmacists’ knowledge of key risk messages and their compliance with the required dispensing practices which had been communicated to them in the training of the additional risk minimization measures. In this study, 345 community pharmacists completed the survey. The survey revealed that respondents (≥80%) demonstrated high level of knowledge of key risk messages through selection of correct answers for 43/51 items in questionnaire. Also, most respondents (90.1%) reported that they were provided with useful/very useful training materials.
What are Avarante 10mg Tablets
In general, if the participants reported having ED, the pharmacists were more likely to assess their suitability for VC and provide advice on appropriate use of VC and on their need to see doctors (Table 6). When stratifying the participants by whether they had been prescribed sildenafil or other ED medication by their doctor (13.8% “Yes”, 78.8% “No”, 7.4% “Do not know/prefer not to answer”), their responses to the question “Since purchasing the FIRST supply of VC from your pharmacist, which of the following are true?” 41.5% of the respondents who reported, vs 12.8% who did not report, having previously been prescribed sildenafil or other ED medication selected the answer “I have seen my doctor and the doctor advised I can continue with sildenafil by buying it at the pharmacy without a prescription”. One of the key strengths of the present study is that it has the benefits of implications from two previously conducted pilot surveys.8,14 The first used a consumer panel and identified significant selection and response biases such that there was a high likelihood that the results would not be representative of the patient population seeking to purchase VC. A second pilot was performed whereby patients were recruited via the pharmacists when the patient was supplied with VC. The survey questions in this second pilot were streamlined to focus only on key questions concerning the advice the pharmacist had provided to the patient, and specifically as to whether the patient was assessed to be suitable for VC and whether he was advised to consult his doctor.
Can I take Viagra Connect with other medicines?
Overall, the findings from these pilot surveys aided in restructuring of the methodology including 1) change in recruitment methods, ie through pharmacists, which ensured that only patients who had definitely been supplied with VC were invited, 2) the streamlining of survey questions to focus more specifically on the patients’ experiences while interacting with the pharmacist to purchase VC and minimize the burden to patients, and 3) the patients recruited were supplied from various types of pharmacies in wide geographical locations. The effectiveness of the UK VC aRMMs program has been substantiated by a previous study, a post-authorization safety study (PASS) and regulatory commitment to UK MHRA, which was a cross-sectional survey of pharmacists in the UK who had dispensed VC as a “behind the counter” product to ED patients who purchased it in their pharmacies. It evaluated the pharmacists’ knowledge of key risk messages and their compliance with the required dispensing practices which had been communicated to them in the training of the additional risk minimization measures. In this study, 345 community pharmacists completed the survey. The survey revealed that respondents (≥80%) demonstrated high level of knowledge of key risk messages through selection of correct answers for 43/51 items in questionnaire. They also opined it was an affirmative experience to provide patient counselling about VC.
How to take HuxD3
The results of this patient survey support the fact that the pharmacists’ knowledge is being put into practice when a patient presents for the first time to purchase VC.14–17 In this patient survey, 51.2% of the patients reported that they were advised, at their first-time purchase of VC, to see their doctor within 6 months or shorter. In the current study, we evaluated the effectiveness of the aRMMs program in a survey of ED patients about their interactions with pharmacists when they first purchased VC in pharmacies. The pharmacist survey has been published allowing us to compare the findings between the patient survey and pharmacist survey.14–16 Regarding pharmacists’ assessment of patients’ suitability for VC at the time the patients purchased VC in pharmacies, most patients in the patient survey reported they had been asked about their BP and heart conditions (91.9%), any other illnesses (87.9%) or concomitant medications use (86.5%). In comparison, with the pharmacist survey, the pharmacists’ level of knowledge on the need to ask patients about cardiovascular disease, other illnesses and medication was generally over 80%. The results of this patient survey support the fact that the pharmacists’ knowledge is being put into practice when a patient presents for the first time to purchase VC.14–17 In this patient survey, 51.2% of the patients reported that they were advised, at their first-time purchase of VC, to see their doctor within 6 months or shorter.